ArticleFrontiers in aging neuroscience2026
Forecasting individualized progression of Alzheimer's disease using structural MRI and population spatiotemporal priors.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Alzheimer's disease (AD), the most common neurodegenerative disorder, involves the progressive loss of vulnerable neurons. Tracking its progression via structural magnetic resonance imaging (sMRI), which captures subtle brain anatomical changes, is vital for advancing diagnosis and treatment. Although generative models show promise in simulating disease progression by forecasting future magnetic resonance imaging (MRI) sequences, generating high-quality MRI with faithful anatomical structures remains challenging. Methods: To narrow this gap, we proposed a progress map-guided generative adversarial network (pg-GAN) that leverages population-level longitudinal data to enhance individual-level prediction. First, progress maps were constructed by averaging intensity residuals between MRI scans acquired at different time points across a population, thereby preserving the comprehensive volumetric evolution of the brain over time. Then, the progress maps served as spatiotemporal priors and were embedded into a backbone generative adversarial network (GAN) via a proposed feature-wise fusion module (FFM) to predict future MRI for individuals. Results: We performed extensive experiments on 210 individuals with longitudinal MRIs from the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset. The results demonstrated that our pg-GAN outperformed other conditioning models. The quantitative results showed that the normalized root mean squared error (NRMSE) decreased from 0.1623 to 0.1549, while the peak signal-to-noise ratio (PSNR) increased from 25.9353 dB to 26.3157 dB. Conclusion: Incorporating group-level progression priors into the generative model can significantly improve the accuracy and anatomical fidelity of predicted MRIs, enhance the visualization of disease progression at the voxel level, and advance the development of precision treatment for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.